about
The role of moxifloxacin in tuberculosis therapyA new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Routine use of microbial whole genome sequencing in diagnostic and public health microbiologyTools for detection of Mycoplasma amphoriforme: a primary respiratory pathogen?Four-month moxifloxacin-based regimens for drug-sensitive tuberculosisGenomic Investigations unmask Mycoplasma amphoriforme, a new respiratory pathogen.Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatmentLimited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy.Sequetyping: serotyping Streptococcus pneumoniae by a single PCR sequencing strategy.Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity.Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study.High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?Managing malaria in tuberculosis patients on fluoroquinolone-containing regimens: assessing the risk of QT prolongation.Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.Defining dormancy in mycobacterial disease.The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations.Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.Chasing Koch's chimera.Optimising molecular diagnostic capacity for effective control of tuberculosis in high-burden settings.Label-free optical vibrational spectroscopy to detect the metabolic state of M. tuberculosis cells at the site of disease.The implications of model-informed drug discovery and development for tuberculosis.Phenotypic resistance in mycobacteria: is it because I am old or fat that I resist you?A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.HspX knock-out in Mycobacterium tuberculosis leads to shorter antibiotic treatment and lower relapse rate in a mouse model--a potential novel therapeutic target.Streptococcus pseudopneumoniae identification by pherotype: a method to assist understanding of a potentially emerging or overlooked pathogen.When is an outbreak not an outbreak? Fit, divergent strains of Mycobacterium tuberculosis display independent evolution of drug resistance in a large London outbreak.Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.Detection and identification of bacteria in clinical samples by 16S rRNA gene sequencing: comparison of two different approaches in clinical practice.Effective anti-tuberculosis therapy correlates with plasma small RNA.A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens.Pseudomonas aeruginosa intensive care unit outbreak: winnowing of transmissions with molecular and genomic typing.Using RT qPCR for Quantifying Mycobacteria marinum from In Vitro and In Vivo Samples.
P50
Q26765372-3EE4B551-040F-4457-A2DD-C8437BB3506FQ28602112-3F7A5066-D00A-4E55-AB9A-114736DB31DEQ28728617-44FEEC97-DD2A-491A-A848-2C56F49712BCQ34400958-1DFFD870-86A6-4A38-A8C4-A2363AE9B663Q34777926-3CD91B6A-3091-48A3-B813-1C96608D4120Q34946001-D6BACC42-0A44-4FF5-8521-BF6CC7427966Q35530606-73134998-0675-4106-8E64-B320E57E35ECQ35915044-4D6AF647-57A3-4BD5-8DCB-80ADC3A952A6Q35983023-063C469B-AA26-435C-8739-47E5DAD24163Q36118755-17308008-0FCC-46A6-887D-21548CB387F7Q37026368-FE856984-B66C-43B2-9021-F57C28AAE554Q37388924-C24243F0-58D6-458D-870E-ED3EBE3E7ED1Q37507802-2683EE62-B89B-4938-A58E-F7A847EEEF6EQ37861939-30408433-2770-4DD7-938C-643857F72CAFQ37975064-52B42178-49FB-4276-B8DD-27E4A0F1A54FQ38161219-CA83393B-7EBB-424D-8605-62EE36E69451Q38199573-26BF7BB5-06B5-4DD3-A2DF-49C899221B1EQ38666266-C306E2D8-9BE7-4FB0-A5B3-C5B16DC5AF26Q38777021-52B35051-E648-4755-9459-6E375335883EQ38852090-1DEE6C4E-A9B2-43D9-9085-291E1D0BCF8AQ38906215-12EF3837-C976-458A-B6E1-8310B5E0320EQ38918532-2E5E8073-5543-458B-9F53-740280C96F7FQ39012547-EFC9C73E-4290-4781-A855-D19D76C0A7CFQ39062681-8E4068B8-16DE-408A-845B-E19D788B0619Q39140159-853469FF-EFE7-4076-BE6C-DE1444A76FD1Q39417890-6973C215-8FE6-4CA0-86DF-DA0A66749053Q40075546-AAF6FA73-AEEA-4115-9EE7-EC90F34537FCQ40487917-A21B9003-4D1C-495D-8263-22855CE68640Q40749409-F7FA44F5-E98F-4C63-928D-53C5297FD036Q41475312-B385C0E9-D949-482D-ADC6-7C18892E2824Q41613893-23762749-37FA-4DA4-AB82-5EE7A233DFB5Q42152399-3C8FF83F-919D-44C3-B4B6-D61724BF2B99Q42287573-ABA79D3A-2292-4C01-B221-7F0592463BCEQ42588101-3C890D53-5FF5-44B0-8072-7C954EF74A35Q43608012-41145907-A817-48C4-AD0C-72258BF3816FQ44006626-0CD61E35-2F75-4F6A-B097-F0F184A88B32Q45138225-8D946858-43EE-4BC4-B055-CF05897966FCQ46046130-CE30671A-0CB7-4485-914D-D494289C8965Q47760001-EC0E9D3F-5704-4190-8AC2-1E93C8F93A83Q50097343-C92C992E-F083-428B-BAB1-7BA8C8B63B58
P50
description
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Stephen H Gillespie
@ast
Stephen H Gillespie
@en
Stephen H Gillespie
@es
Stephen H Gillespie
@nl
Stephen H Gillespie
@sl
type
label
Stephen H Gillespie
@ast
Stephen H Gillespie
@en
Stephen H Gillespie
@es
Stephen H Gillespie
@nl
Stephen H Gillespie
@sl
prefLabel
Stephen H Gillespie
@ast
Stephen H Gillespie
@en
Stephen H Gillespie
@es
Stephen H Gillespie
@nl
Stephen H Gillespie
@sl
P106
P21
P214
1302145856948822920526
P31
P496
0000-0001-6537-7712